Fig. 1

The effects of granulocyte depletion on bispecific antibody (BsAb) directed T cell immunotherapy. A Neuroblastoma patient-derived xenografts (PDXs) treated with GD2-BsAb armed T cells (GD2-EATs) or unarmed T cells were compared with untreated tumors. All tumors were harvested on day 10 after the start of treatment. Immunohistochemical (IHC) staining of the tumor sections by anti-human CD3 antibody (× 10), anti-human CD4 antibody (× 10), anti-CD8 antibody (× 10), anti-mouse IBA1 antibody (× 10), and anti-mouse CD45 antibody (x 10). a, no treatment; b, unarmed T cells; c, GD2-EATs. B Neuroblastoma PDX bearing mice were treated by GD2-EATs with anti-Ly6G antibody to deplete granulocytes. C The complete blood count (CBC) test was done and compared among groups. D Tumors harvested on day 10 were analyzed by flow cytometry (Additional file 1: Fig. S3), and the frequencies of each tumor infiltrating leukocytes were compared among groups. E The PDXs treated with GD2-EATs plus anti-Ly6G antibody were harvested on day 10 after the start of treatment and were stained by anti-human CD3 antibody (× 10), anti-human CD4 antibody (× 10), anti-CD8 antibody (× 10), anti-mouse IBA1 antibody (× 10)